Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07MEH
|
|||
| Former ID |
DAP001495
|
|||
| Drug Name |
Meglitinides
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11] | Approved | [1] | |
| Psychotic disorder [ICD-11: 6A20-6A25] | Phase 4 | [2], [3] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H20Cl2N2O3
|
|||
| Canonical SMILES |
CCN1CCCC1CNC(=O)C2=C(C(=CC(=C2OC)Cl)Cl)O
|
|||
| InChI |
1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)/t9-/m0/s1
|
|||
| InChIKey |
WAOQONBSWFLFPE-VIFPVBQESA-N
|
|||
| CAS Number |
CAS 84225-95-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980481, 10047782, 11114224, 12013470, 14827538, 26719717, 26752250, 36077621, 46386981, 47515551, 47810996, 48185204, 49681662, 50104962, 53787975, 57352765, 77953791, 85788759, 90340860, 91746408, 92308273, 92308736, 103167993, 103918664, 111634979, 124658776, 124800057, 124887054, 129553949, 134338685, 134340417, 135014074, 135650880, 135698402, 137237422, 142971008, 144204512, 152106370, 160821969, 162023238, 163091727, 163383825, 170466218, 170485724, 172080125, 172860716, 176484026, 178100336, 179151282, 198978423
|
|||
| ChEBI ID |
CHEBI:92070
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 94). | |||
| REF 3 | ClinicalTrials.gov (NCT02020408) Monoamine Contributions to Neurocircuitry in Eating Disorders. U.S. National Institutes of Health. | |||
| REF 4 | Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol. 1985 Jul 1;34(13):2251-9. | |||
| REF 5 | The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience. 1996 Jan;70(2):377-89. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.